📉 How Much LDL-C Lowering Matters
Knowing LDL-C improved isn’t the same as knowing you’ve lowered it enough. VESALIUS-CV measured the magnitude of reduction PCSK9 inhibition can achieve, and the results were substantial.
In the lipid sub-study, median LDL-C started at about 115 mg/dL.
📊 At 48 weeks: 45 mg/dL with evolocumab vs. 109 mg/dL with placebo
📉 55% placebo-adjusted LDL-C reduction
✅ Greater reduction, fewer events
This mirrors earlier evidence from FOURIER, where evolocumab lowered LDL-C by approximately 59%, an absolute reduction of 56 mg/dL on top of statin therapy.
The clinical lesson: don’t just ask whether LDL-C improved. Ask whether you’ve achieved enough reduction for that patient’s level of risk.
Magnitude of LDL-C reduction matters.
🎥 Watch the full breakdown in our latest reel.
Supported by an educational grant from Amgen. ASPC maintains full editorial oversight and approval of program content.
Learn more: aspconline.org/pcsk9-education
#VESALIUSCV #PCSK9 #PreventiveCardiology #CardiovascularHealth #LDLC
Knowing LDL-C improved isn’t the same as knowing you’ve lowered it enough. VESALIUS-CV measured the magnitude of reduction PCSK9 inhibition can achieve, and the results were substantial.
In the lipid sub-study, median LDL-C started at about 115 mg/dL.
📊 At 48 weeks: 45 mg/dL with evolocumab vs. 109 mg/dL with placebo
📉 55% placebo-adjusted LDL-C reduction
✅ Greater reduction, fewer events
This mirrors earlier evidence from FOURIER, where evolocumab lowered LDL-C by approximately 59%, an absolute reduction of 56 mg/dL on top of statin therapy.
The clinical lesson: don’t just ask whether LDL-C improved. Ask whether you’ve achieved enough reduction for that patient’s level of risk.
Magnitude of LDL-C reduction matters.
🎥 Watch the full breakdown in our latest reel.
Supported by an educational grant from Amgen. ASPC maintains full editorial oversight and approval of program content.
Learn more: aspconline.org/pcsk9-education
#VESALIUSCV #PCSK9 #PreventiveCardiology #CardiovascularHealth #LDLC
1:11
